Compare DexCom, Inc. (DXCM) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vale SA — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Vale SA trades at $13.62 (market cap $57.32B). The key difference: Vale SA is the larger of the two by market cap, and Vale SA pays a 8.87% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Vale SA for 109 Days on average.
| DXCM | VALE | |
|---|---|---|
Market Cap | $31.86B | $57.32B |
Volume | 3,607,070 | 27,996,846 |
Sector | Health | Basic Materials |
52-Week High | $92.34 | $17.82 |
52-Week Low | $54.84 | $10.75 |
Typical Hold Time | 62 Days | 109 Days |
Enterprise Value | $31.32B | $73.56B |
Dividend Yield | — | 8.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
VALE trades at $13.42, down 1.4% today, amid bearish technical signals and recent earnings misses. The stock shows mixed fundamentals with a P/E of 26.84 and net income margin of 5.11%, while cash flow improved to $2.42B in 2025. Recent news highlights pressure from U.S. steel expansion plans and rising costs, though base metals growth offers some offset.
Outlook remains cautious with 32% analyst buy ratings but significant earnings volatility. Upside exists if copper growth accelerates and iron ore stabilizes, but regulatory risks in Brazil and cost inflation pose headwinds. The consensus price target of $16.21 suggests 21% potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
